Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$104.77 USD
-0.47 (-0.45%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $104.41 -0.36 (-0.34%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum C VGM
Brokerage Reports
0 items in cart
Abbott Laboratories [ABT]
Reports for Purchase
Showing records 401 - 420 ( 534 total )
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Strengthening U.S. Dollar to be a major headwind in 2015, as 70% of ABT?s sales comes from
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Stable - improved growth prospects and increasing Emerging Markets mix augur well
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Management raises mid-point of CY14 EPS guidance range - expects strong double-digit EPS growth for CY14 and ahead...
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Management reiterates guidance of strong earnings growth of 10%, going forward, with performance in CY14 expected to be back-end loaded towards H2CY14....
Provider: FIRST GLOBAL
Analyst: THOMAS K